Flexion discovers and develops innovative therapeutics for musculoskeletal disorders. To provide products with superior efficacy and safety, we are merging novel pharmacology with local, sustained delivery of drug to the locus of disease — an approach that ensures lasting therapeutic effect and systemic safety. Our first products represent substantial advances in the treatment of osteoarthritis, a leading cause of disability that affects more than 27 million adults in the U.S. and more than 100 million people worldwide. We are currently advancing best-in-class drug candidates that have the potential to treat mild, moderate and severe forms of this debilitating disorder.
